Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial
Abstract
Blinatumomab has shown promise in improving the initial treatment of acute B-cell precursor lymphoblastic leukemia (BCP-ALL). To reduce side effects and improve effectiveness, we conducted a phase 2 trial using reduced-dose chemotherapy (RDC) followed by blinatumomab for newly diagnosed patients with Ph-negative BCP-ALL. The trial resulted in a high rate of complete remission and measurable residual disease negativity, supporting the approach of using RDC followed by blinatumomab as an effective and well-tolerated induction regimen.
Clinical Trial Results
Of the 35 enrolled patients, 94% achieved complete remission after 2 weeks of blinatumomab, with 86% achieving measurable residual disease negativity. All patients achieved complete remission with either 2 or 4 weeks of blinatumomab treatment, with limited immune effector cell-associated neurotoxicity syndrome and manageable non-hematological adverse events. The estimated 1-year overall survival and progression-free survival rates were 97.1% and 82.2%, respectively.
Practical Solutions and Value
These findings support a shift towards less intensive and more targeted therapeutic approaches for newly diagnosed Ph-negative BCP-ALL. Clinical trials play a key role in developing safe and effective treatments, and it’s important to incorporate their benefits into everyday medical practice. Our AI-driven platform, DocSym, consolidates clinical protocols and research into an easily accessible knowledge base for clinicians, helping to streamline operations and improve patient care. Additionally, our mobile apps support scheduling, monitoring treatments, and telemedicine, enabling clinics to expand services digitally and enhance workflows.
By utilizing AI and digital tools, clinics can improve patient outcomes, reduce paper routines, and enhance their overall workflows. Learn more about how we can help at aidevmd.com.
